Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoLazer in EGFR-mutated Resectable NSCLC
NCT06268210Phase 2Active, not recruiting
- Sponsor
- Yonsei University
- Start
- Feb 2022
- Primary completion
- May 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of lazertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yonsei University. Primary endpoint: Primary pathological response at 3 months. Started Feb 2022; status: active, not recruiting.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06268210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268210.